OcuTer­ra’s di­a­bet­ic retinopa­thy drug fails PhII; Bet­ter Ther­a­peu­tics to shut down

Plus, news about Im­muneer­ing, Adi­tum Bio, Uni­cy­cive and X-Ther­ma:

OcuTer­ra Ther­a­peu­tics’ di­a­bet­ic retinopa­thy drug fails PhII: The com­pa­ny’s RGD in­te­grin in­hibitor did not meet the pri­ma­ry end­point of per­cent­age of pa­tients with a min­i­mum two-step im­prove­ment in the di­a­bet­ic retinopa­thy sever­i­ty scale ver­sus place­bo. OcuTer­ra said it is re­view­ing the da­ta to “eval­u­ate the fu­ture” of the nes­vate­grast pro­gram. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER